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Abstract
Introduction: Type II mixed cryoglobulin syndrome is a systematic vasculitis mainly linked to
immune complex deposition in several organs and to hepatitis C virus infection. Therapeutic
strategies can target either the viral trigger hepatitis C virus if present, or pathogenic events
downstream the triggering infection, e.g, the proliferation B-cells directly. Antiviral therapy should be
considered as a first-line treatment in many HCV-positive patients. However, it may prove ineffective,
contraindicated, or poorly tolerated. The other available treatment [such as cytotoxic agents,
steroids] may lead to life-threatening complications and may be difficult to manage in the long term.
Case presentation: We report on a 75-year-old patient with long-lasting hepatitis C virus infection
[18 years], a long-lasting cryoglobulinemia [7 years] resistant to common antiviral therapy, diabetes
mellitus and deep skin ulcers, successfully treated with the combination therapy of Rituximab and
plasma exchange.
Conclusion: Plasma exchange in combination with Rituximab may be useful to heal skin in those
patients who are non responsive to Rituximab alone, by avoiding a leg amputation.
Introduction
Type II mixed cryoglobulinemia (tIIMC ) is a systemic
vasculitis caused by immune complexes formed by
monoclonal IgM rheumatoid factor and polyclonal IgG
[1]. In the large majority of cases, this disorder is caused by
chronic hepatitis C virus infection [2]. The immunological
mechanism underlying tIIMC consists on the HCV-driven
monoclonal expansion of a subset of CD20+, CD27+
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[3]. Therefore, the therapy of tIIMC can be focused on
inhibition of viral replication or on inhibition of B-cell
proliferation. Eradication of HCV infection by antiviral
treatment usually leads to the disappearance of cryoglo-
bulins and the regression of vasculitis [4,5], but several
patients are resistant to antiviral therapy or cannot be
treated because of side effects or contraindications.
Recently, anti B cell therapy with rituximab has been
proposed as salvage treatment for patients failing to
respond to antiviral therapy [6-11]. Rituximab (RTX), a
mouse/human chimeric monoclonal anti-CD20 antibody,
selectively targets the B-cell compartment from B-cell step
to plasma cells, and results in prolonged depletion of
normal B-cells from peripheral blood [12]. RTX is
approved for the treatment of non-aggressive non-Hodg-
kin lymphoma [13]. Given the good safety profile and the
role of B-cells as antigen-presenting cells or pathogenic
antibody producers in many autoimmune disorders, RTX
has been used off-label for numerous patients suffering
from a great variety of autoimmune diseases [14,15].
Therefore RTX has been successfully employed in tIIMC
patients, including HCV-negative and alpha-interferon
resistant patients. We report a successful treatment of a
patient with cryoglobulinemic vasculitis presenting with
skin ulcers, with a combination of rituximab and plasma
exchange.
Case presentation
A 75-year-old Caucasian Italian man was admitted because
ofulcersonleftleg.Hispastmedicalhistorywasrelevant for
a long-lasting (18 years) HCV infection and a long-
lasting (7 years) tIIMC resistant to antiviral therapy. He
had been undergone an antiviral therapy with a combina-
tion of alpha interferon, Ribavirin and prednisolone,
with a significant reduction of HCV activity, as demon-
strated by a reduction of HCV-RNA levels (800000 UI/L to
13000 UI/L), but without reduction of cryocrit and B-cells
(cryocrit 93/μL and B-cells 286/μL). After two years of
therapy discontinuation, the patient was admitted at our
unit. The HCV activity, cryocrit and B-cell levels were very
high (800000 UI/L, 132/μL, 412 B-cells/μl respectively).
The leg ulcers measured 8 × 6 cm and 10 × 5 cm and were
veryachingwithsignsofinfection(Figure1).Westartedan
antiviral therapy with prednisolone, Interferon-a and
Ribavirin which brought to a important reduction of HCV
activity (from 800000 UI/L to 54000 UI/L) with slight
reduction of cryocrit (132/μLt o1 1 2 / μL) and B-cells
(412/μL to 338/μL). After two weeks of treatment there
was no significant improvement in ulcer’s healing so we
started a therapy withRituximab. We administered a single
course of RTX at a dose of 375 mg/m
2 weekly for 4 weeks,
and one course of 375 mg/m
2 every two months as
maintenance regimen. Our patient showed a mild reaction
during the first infusion of RTX (mild hypotension and
tremor) easily controlled with steroids administration.
TreatmentwithRTXresultedinaslightreductionofcryocrit
and B-cells, without significant improvement on ulcer’s
healing. Finally, the patient underwent five sessions of
plasma exchange to reduce cryocrit and a dose of RTX of
375 mg/m
2 was administered. This treatment resulted in
reduction of cryocrit (2 /μL) and B-cells (205 /μL) and the
skinulcersimprovedwithimportantreductionofpain.The
skin ulcers completely recovered in 6 months (Figure 2).
Discussion
Type II mixed cryoglobulinemia is the result of mono-
clonal IgM paraprotein with rheumatoid activity binding
Figure 1. Ulcer to the leg extending to the medial (A) and the anterior (B) part of the foot.
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complexes, complement activation, vasculitis, and gro-
merulonephritis. tIIMC often is associated with chronic
HCV infection.
Patients with a long -lasting tIIMC often are non
responders to antiviral therapies. Our patient was unsuc-
cessfully treated with antiviral therapy and Rituximab, and
only a combination with RTX and plasma exchange
resulted in a clinical improvement. We may speculate
that plasma exchange therapy may have removed some
immune complexes that can bind part of RTX, and
significantly reduced cryocrit and rheumatoid factor, by
finally improving the efficacy of Rituximab.
Conclusions
After the failure of RTX the only possibility to kill pain in a
patient with skin ulcers is amputation. Plasma exchange in
combination with RTX can be useful to heal skin in those
patients who are non responsive to RTX alone, by avoiding
a leg amputation. The mechanism remains unknown.
Further studies will be useful to define if the combination
of plasma exchange with RTX can be used in all patients
unresponsive to RTX or antiviral therapies.
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